Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Contact

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
options
options_strategies
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Rhythm Pharmaceuticals Inc (RYTM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Notes

Alerts

Watch

Help

Rhythm Pharmaceuticals Announces Positive Weight Reduction Results in Pediatric Patients Treated with Setmelanotide in Early-Access Program and Plans New Substudy for Congenital Hypothalamic Obesity Quiver Quantitative, Inc. - Mon Nov 18, 4:16PM CST

Four pediatric patients using setmelanotide therapy showed significant weight loss in a French early-access program, prompting further study.Quiver AI SummaryRhythm Pharmaceuticals announced promising...

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide GlobeNewswire - Mon Nov 18, 6:00AM CST

Rhythm Pharmaceuticals Publishes Positive Phase 3 VENTURE Trial Results for Setmelanotide in Young Children with Rare Genetic Obesity Conditions Quiver Quantitative, Inc. - Thu Nov 14, 4:00AM CST

Rhythm Pharmaceuticals reports Phase 3 trial results showing setmelanotide reduces hunger and weight in young children with severe obesity.Quiver AI SummaryRhythm Pharmaceuticals announced positive results...

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology GlobeNewswire - Wed Nov 13, 5:30PM CST

Rhythm Pharmaceuticals Announces New Employment Inducement Grants GlobeNewswire - Wed Nov 13, 3:01PM CST

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences GlobeNewswire - Wed Nov 6, 7:00AM CST

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update GlobeNewswire - Tue Nov 5, 3:01PM CST

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 GlobeNewswire - Mon Nov 4, 3:01PM CST

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome GlobeNewswire - Thu Oct 24, 5:00AM CDT

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 GlobeNewswire - Wed Oct 23, 7:00AM CDT